Cargando…

Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy

PURPOSE: Hesketh scores define emetogenicity of single-agent and multiagent single-day chemotherapy. This analysis determined the emetogenicity of multiagent, multiday chemotherapy and the Granisetron Transdermal System (GTDS; Sancuso(®)). METHODS: This was a retrospective analysis of a multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccia, Ralph V, Clark, Gemma, Howell, Julian D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421466/
https://www.ncbi.nlm.nih.gov/pubmed/22904638
http://dx.doi.org/10.2147/CMAR.S31349
_version_ 1782240965078024192
author Boccia, Ralph V
Clark, Gemma
Howell, Julian D
author_facet Boccia, Ralph V
Clark, Gemma
Howell, Julian D
author_sort Boccia, Ralph V
collection PubMed
description PURPOSE: Hesketh scores define emetogenicity of single-agent and multiagent single-day chemotherapy. This analysis determined the emetogenicity of multiagent, multiday chemotherapy and the Granisetron Transdermal System (GTDS; Sancuso(®)). METHODS: This was a retrospective analysis of a multicenter, randomized, double-blind, phase III noninferiority trial of GTDS versus oral granisetron in patients receiving 3 days of multiagent moderately or highly emetogenic chemotherapy, regardless of granisetron formulation. Emesis was defined as vomiting/retching or the use of rescue medication. Logistic regression and classification trees were used to determine the optimal combination of Hesketh scores over the multiagent, multiday regimens for the prediction of emesis. RESULTS: Of 393 patients, 272 (69.2%) were chemotherapy naïve. The most common types of cancer were lung (30.5%) and gynecologic (21.9%). The most common chemotherapeutic regimen (in 14.2% of patients) was cisplatin plus etoposide on days 1–3. The best binary emesis predictor was day 1 Hesketh score. Patients with a day 1 Hesketh score of 5 had the highest rate of emesis (62.5%) versus patients with a score < 5 (31.7%). For patients with day 1 Hesketh score < 5, only 14.3% of those receiving only one drug on day 1 experienced emesis. CONCLUSION: Hesketh emetogenicity scores of individual agents are applicable to multiday, multiagent chemotherapeutic regimens in patients receiving antiemetics.
format Online
Article
Text
id pubmed-3421466
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34214662012-08-19 Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy Boccia, Ralph V Clark, Gemma Howell, Julian D Cancer Manag Res Short Report PURPOSE: Hesketh scores define emetogenicity of single-agent and multiagent single-day chemotherapy. This analysis determined the emetogenicity of multiagent, multiday chemotherapy and the Granisetron Transdermal System (GTDS; Sancuso(®)). METHODS: This was a retrospective analysis of a multicenter, randomized, double-blind, phase III noninferiority trial of GTDS versus oral granisetron in patients receiving 3 days of multiagent moderately or highly emetogenic chemotherapy, regardless of granisetron formulation. Emesis was defined as vomiting/retching or the use of rescue medication. Logistic regression and classification trees were used to determine the optimal combination of Hesketh scores over the multiagent, multiday regimens for the prediction of emesis. RESULTS: Of 393 patients, 272 (69.2%) were chemotherapy naïve. The most common types of cancer were lung (30.5%) and gynecologic (21.9%). The most common chemotherapeutic regimen (in 14.2% of patients) was cisplatin plus etoposide on days 1–3. The best binary emesis predictor was day 1 Hesketh score. Patients with a day 1 Hesketh score of 5 had the highest rate of emesis (62.5%) versus patients with a score < 5 (31.7%). For patients with day 1 Hesketh score < 5, only 14.3% of those receiving only one drug on day 1 experienced emesis. CONCLUSION: Hesketh emetogenicity scores of individual agents are applicable to multiday, multiagent chemotherapeutic regimens in patients receiving antiemetics. Dove Medical Press 2012-07-03 /pmc/articles/PMC3421466/ /pubmed/22904638 http://dx.doi.org/10.2147/CMAR.S31349 Text en © 2012 Boccia et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Short Report
Boccia, Ralph V
Clark, Gemma
Howell, Julian D
Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
title Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
title_full Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
title_fullStr Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
title_full_unstemmed Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
title_short Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy
title_sort use of transdermal and intravenous granisetron and the ability of the hesketh score to assess nausea and vomiting induced by multiday chemotherapy
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421466/
https://www.ncbi.nlm.nih.gov/pubmed/22904638
http://dx.doi.org/10.2147/CMAR.S31349
work_keys_str_mv AT bocciaralphv useoftransdermalandintravenousgranisetronandtheabilityoftheheskethscoretoassessnauseaandvomitinginducedbymultidaychemotherapy
AT clarkgemma useoftransdermalandintravenousgranisetronandtheabilityoftheheskethscoretoassessnauseaandvomitinginducedbymultidaychemotherapy
AT howelljuliand useoftransdermalandintravenousgranisetronandtheabilityoftheheskethscoretoassessnauseaandvomitinginducedbymultidaychemotherapy